Loading…

Reversible suppression of sexual activity in tomcats with deslorelin implant

The aim of the study was to assess the efficacy of using a Gn-RH agonist implant (deslorelin, 4.7 mg, Suprelorin) to control sexual activity of male cats and reestablishment of sexual function after the implant removal 4 mo after placement. Using a control group (Group 1, n = 5), 22 domestic tomcats...

Full description

Saved in:
Bibliographic Details
Published in:Theriogenology 2012-09, Vol.78 (4), p.848-857
Main Authors: Novotny, R., Cizek, P., Vitasek, R., Bartoskova, A., Prinosilova, P., Janosovska, M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c410t-20c38c44fb4fb8b5d6e137b550ea3234abfb1cce331dbb17eeeaeb671f3bd3a93
cites cdi_FETCH-LOGICAL-c410t-20c38c44fb4fb8b5d6e137b550ea3234abfb1cce331dbb17eeeaeb671f3bd3a93
container_end_page 857
container_issue 4
container_start_page 848
container_title Theriogenology
container_volume 78
creator Novotny, R.
Cizek, P.
Vitasek, R.
Bartoskova, A.
Prinosilova, P.
Janosovska, M.
description The aim of the study was to assess the efficacy of using a Gn-RH agonist implant (deslorelin, 4.7 mg, Suprelorin) to control sexual activity of male cats and reestablishment of sexual function after the implant removal 4 mo after placement. Using a control group (Group 1, n = 5), 22 domestic tomcats were given the implant subcutaneously in the region of the right shoulder blade and were then divided into two treatment groups. Animals in Group 2 (n = 14) were observed from the date of implant surgery and the observation lasted for 4 mo. In Group 3 (n = 8) all animals were monitored from the date of implant surgery. Then, after 4 mo, all implants were removed and the toms were observed for a further 4 mo. In all animals during their first visit and then in 1-mo intervals, changes in testosterone concentrations were assessed before (T0) and 4 h after (T4) human chorionic gonadotropin (HCG) administration and testis size was measured. In all tomcats, semen collection was performed, using an electroejaculator, in the course of the first visit and then in 2-mo intervals or at the end of observation. Total sperm count was determined in each semen sample. Two to four animals were castrated at weeks 4, 8, 12, 16, 20, 24, 28 and 32 and histologic assessment of the testes was performed. By evaluation of 200 cross sections of seminiferous tubules, the degree of spermatogenic suppression was assessed and animals in Groups 2 and 3 were assigned into groups according to most tubules with the most developed germ cell observed: G1, spermatocytes; G2, round spermatids; G3, elongating spermatids and G4, elongated spermatids. The mean area of Leydig-cell nuclei was calculated. In animals in Group 2, suppression after implant insertion was monitored. T4 concentrations, testis size, and total sperm count gradually decreased (P < 0.01; P < 0.01; and P < 0.05, respectively) within 4 mo after implantation. Histologic evaluation showed a high individual variation in the degree of suppression of spermatogenesis. In animals in Group 3, the implant was removed 4 mo after insertion and the return of sexual activity was monitored. Within 4 mo, T4 concentration and total sperm count increased to the physiological values of intact toms. Testes gradually increased in size and within 4 mo of implant removal almost reached pretreatment size. According to histologic evaluation of the seminiferous tubules, as early as 1 mo after implant removal, all animals were assigned to G4, with most tubul
doi_str_mv 10.1016/j.theriogenology.2012.03.035
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1030505628</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0093691X12002087</els_id><sourcerecordid>1030505628</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-20c38c44fb4fb8b5d6e137b550ea3234abfb1cce331dbb17eeeaeb671f3bd3a93</originalsourceid><addsrcrecordid>eNqNkE1rGzEQhkVJaJy0f6HdQw69rKNZ7ZehlxKSJmAIJDX0JiTtrCOzu9potG797ytjN5BbxAsC8czo5WHsEvgcOJRXm3l4Rm_dGgfXufVunnHI5lzEFB_YDOpqkYpMwAmbcb4QabmA32fsnGjDORdlCR_ZWZYVVV1CNWPLR9yiJ6s7TGgaR49E1g2JaxPCv5PqEmWC3dqwS-yQBNcbFSj5Y8Nz0iB1zmMX320_dmoIn9hpqzrCz8f7gq1ub35d36XLh5_31z-WqcmBhzTjRtQmz1sdU-uiKRFEpYuCo4rNc6VbDcagENBoDRUiKtRlBa3QjVALccG-HfaO3r1MSEH2lgx2sQO6iSRwwQtelFkd0e8H1HhH5LGVo7e98rsIyb1PuZFvfcq9T8lFTBHHvxx_mnSPzevwf4ER-HoAWuWkWntLcvUUN-RRNsSzb3B7IDAa2Vr0kozFwWBjPZogG2ff1-UfgoKbig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1030505628</pqid></control><display><type>article</type><title>Reversible suppression of sexual activity in tomcats with deslorelin implant</title><source>ScienceDirect Journals</source><creator>Novotny, R. ; Cizek, P. ; Vitasek, R. ; Bartoskova, A. ; Prinosilova, P. ; Janosovska, M.</creator><creatorcontrib>Novotny, R. ; Cizek, P. ; Vitasek, R. ; Bartoskova, A. ; Prinosilova, P. ; Janosovska, M.</creatorcontrib><description>The aim of the study was to assess the efficacy of using a Gn-RH agonist implant (deslorelin, 4.7 mg, Suprelorin) to control sexual activity of male cats and reestablishment of sexual function after the implant removal 4 mo after placement. Using a control group (Group 1, n = 5), 22 domestic tomcats were given the implant subcutaneously in the region of the right shoulder blade and were then divided into two treatment groups. Animals in Group 2 (n = 14) were observed from the date of implant surgery and the observation lasted for 4 mo. In Group 3 (n = 8) all animals were monitored from the date of implant surgery. Then, after 4 mo, all implants were removed and the toms were observed for a further 4 mo. In all animals during their first visit and then in 1-mo intervals, changes in testosterone concentrations were assessed before (T0) and 4 h after (T4) human chorionic gonadotropin (HCG) administration and testis size was measured. In all tomcats, semen collection was performed, using an electroejaculator, in the course of the first visit and then in 2-mo intervals or at the end of observation. Total sperm count was determined in each semen sample. Two to four animals were castrated at weeks 4, 8, 12, 16, 20, 24, 28 and 32 and histologic assessment of the testes was performed. By evaluation of 200 cross sections of seminiferous tubules, the degree of spermatogenic suppression was assessed and animals in Groups 2 and 3 were assigned into groups according to most tubules with the most developed germ cell observed: G1, spermatocytes; G2, round spermatids; G3, elongating spermatids and G4, elongated spermatids. The mean area of Leydig-cell nuclei was calculated. In animals in Group 2, suppression after implant insertion was monitored. T4 concentrations, testis size, and total sperm count gradually decreased (P &lt; 0.01; P &lt; 0.01; and P &lt; 0.05, respectively) within 4 mo after implantation. Histologic evaluation showed a high individual variation in the degree of suppression of spermatogenesis. In animals in Group 3, the implant was removed 4 mo after insertion and the return of sexual activity was monitored. Within 4 mo, T4 concentration and total sperm count increased to the physiological values of intact toms. Testes gradually increased in size and within 4 mo of implant removal almost reached pretreatment size. According to histologic evaluation of the seminiferous tubules, as early as 1 mo after implant removal, all animals were assigned to G4, with most tubules containing elongated spermatids as the most developed germ cells. Treatment with the long-term subcutaneous Gn-RH agonist implant was well tolerated and no adverse treatment-related effects were noted. These results demonstrated efficacy of 4.7 mg deslorelin implant (Suprelorin) with high variability of the effect onset in tomcats. Furthermore, the study revealed a strong need for complex examination, including testis size measurement, monitoring of hormonal changes, spermatological analysis and histologic evaluation, to declare the animal infertile. After the implant removal, all observed parameters confirmed the reversibility of the method and gradual return of sexual activity in toms.</description><identifier>ISSN: 0093-691X</identifier><identifier>EISSN: 1879-3231</identifier><identifier>DOI: 10.1016/j.theriogenology.2012.03.035</identifier><identifier>PMID: 22578617</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>agonists ; Animals ; cats ; Cats - anatomy &amp; histology ; Cats - blood ; Cats - physiology ; Contraception - methods ; Contraception - veterinary ; Contraceptive Agents, Male - administration &amp; dosage ; Down-Regulation - drug effects ; Drug Implants ; Ejaculation - drug effects ; Ejaculation - physiology ; germ ; GnRH-agonist ; Histologic evaluation ; human chorionic gonadotropin ; Male ; Male cat ; Organ Size - drug effects ; Osmolar Concentration ; Recovery of Function - drug effects ; Recovery of Function - physiology ; semen ; Semen collection ; seminiferous tubules ; Sexual Behavior, Animal - drug effects ; Sexual Behavior, Animal - physiology ; spermatids ; spermatocytes ; spermatozoa ; surgery ; Testis - anatomy &amp; histology ; Testis - drug effects ; Testis - physiology ; Testis size ; testosterone ; Testosterone - blood ; Triptorelin Pamoate - administration &amp; dosage ; Triptorelin Pamoate - analogs &amp; derivatives ; Withholding Treatment</subject><ispartof>Theriogenology, 2012-09, Vol.78 (4), p.848-857</ispartof><rights>2012 Elsevier Inc.</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-20c38c44fb4fb8b5d6e137b550ea3234abfb1cce331dbb17eeeaeb671f3bd3a93</citedby><cites>FETCH-LOGICAL-c410t-20c38c44fb4fb8b5d6e137b550ea3234abfb1cce331dbb17eeeaeb671f3bd3a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22578617$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Novotny, R.</creatorcontrib><creatorcontrib>Cizek, P.</creatorcontrib><creatorcontrib>Vitasek, R.</creatorcontrib><creatorcontrib>Bartoskova, A.</creatorcontrib><creatorcontrib>Prinosilova, P.</creatorcontrib><creatorcontrib>Janosovska, M.</creatorcontrib><title>Reversible suppression of sexual activity in tomcats with deslorelin implant</title><title>Theriogenology</title><addtitle>Theriogenology</addtitle><description>The aim of the study was to assess the efficacy of using a Gn-RH agonist implant (deslorelin, 4.7 mg, Suprelorin) to control sexual activity of male cats and reestablishment of sexual function after the implant removal 4 mo after placement. Using a control group (Group 1, n = 5), 22 domestic tomcats were given the implant subcutaneously in the region of the right shoulder blade and were then divided into two treatment groups. Animals in Group 2 (n = 14) were observed from the date of implant surgery and the observation lasted for 4 mo. In Group 3 (n = 8) all animals were monitored from the date of implant surgery. Then, after 4 mo, all implants were removed and the toms were observed for a further 4 mo. In all animals during their first visit and then in 1-mo intervals, changes in testosterone concentrations were assessed before (T0) and 4 h after (T4) human chorionic gonadotropin (HCG) administration and testis size was measured. In all tomcats, semen collection was performed, using an electroejaculator, in the course of the first visit and then in 2-mo intervals or at the end of observation. Total sperm count was determined in each semen sample. Two to four animals were castrated at weeks 4, 8, 12, 16, 20, 24, 28 and 32 and histologic assessment of the testes was performed. By evaluation of 200 cross sections of seminiferous tubules, the degree of spermatogenic suppression was assessed and animals in Groups 2 and 3 were assigned into groups according to most tubules with the most developed germ cell observed: G1, spermatocytes; G2, round spermatids; G3, elongating spermatids and G4, elongated spermatids. The mean area of Leydig-cell nuclei was calculated. In animals in Group 2, suppression after implant insertion was monitored. T4 concentrations, testis size, and total sperm count gradually decreased (P &lt; 0.01; P &lt; 0.01; and P &lt; 0.05, respectively) within 4 mo after implantation. Histologic evaluation showed a high individual variation in the degree of suppression of spermatogenesis. In animals in Group 3, the implant was removed 4 mo after insertion and the return of sexual activity was monitored. Within 4 mo, T4 concentration and total sperm count increased to the physiological values of intact toms. Testes gradually increased in size and within 4 mo of implant removal almost reached pretreatment size. According to histologic evaluation of the seminiferous tubules, as early as 1 mo after implant removal, all animals were assigned to G4, with most tubules containing elongated spermatids as the most developed germ cells. Treatment with the long-term subcutaneous Gn-RH agonist implant was well tolerated and no adverse treatment-related effects were noted. These results demonstrated efficacy of 4.7 mg deslorelin implant (Suprelorin) with high variability of the effect onset in tomcats. Furthermore, the study revealed a strong need for complex examination, including testis size measurement, monitoring of hormonal changes, spermatological analysis and histologic evaluation, to declare the animal infertile. After the implant removal, all observed parameters confirmed the reversibility of the method and gradual return of sexual activity in toms.</description><subject>agonists</subject><subject>Animals</subject><subject>cats</subject><subject>Cats - anatomy &amp; histology</subject><subject>Cats - blood</subject><subject>Cats - physiology</subject><subject>Contraception - methods</subject><subject>Contraception - veterinary</subject><subject>Contraceptive Agents, Male - administration &amp; dosage</subject><subject>Down-Regulation - drug effects</subject><subject>Drug Implants</subject><subject>Ejaculation - drug effects</subject><subject>Ejaculation - physiology</subject><subject>germ</subject><subject>GnRH-agonist</subject><subject>Histologic evaluation</subject><subject>human chorionic gonadotropin</subject><subject>Male</subject><subject>Male cat</subject><subject>Organ Size - drug effects</subject><subject>Osmolar Concentration</subject><subject>Recovery of Function - drug effects</subject><subject>Recovery of Function - physiology</subject><subject>semen</subject><subject>Semen collection</subject><subject>seminiferous tubules</subject><subject>Sexual Behavior, Animal - drug effects</subject><subject>Sexual Behavior, Animal - physiology</subject><subject>spermatids</subject><subject>spermatocytes</subject><subject>spermatozoa</subject><subject>surgery</subject><subject>Testis - anatomy &amp; histology</subject><subject>Testis - drug effects</subject><subject>Testis - physiology</subject><subject>Testis size</subject><subject>testosterone</subject><subject>Testosterone - blood</subject><subject>Triptorelin Pamoate - administration &amp; dosage</subject><subject>Triptorelin Pamoate - analogs &amp; derivatives</subject><subject>Withholding Treatment</subject><issn>0093-691X</issn><issn>1879-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkE1rGzEQhkVJaJy0f6HdQw69rKNZ7ZehlxKSJmAIJDX0JiTtrCOzu9potG797ytjN5BbxAsC8czo5WHsEvgcOJRXm3l4Rm_dGgfXufVunnHI5lzEFB_YDOpqkYpMwAmbcb4QabmA32fsnGjDORdlCR_ZWZYVVV1CNWPLR9yiJ6s7TGgaR49E1g2JaxPCv5PqEmWC3dqwS-yQBNcbFSj5Y8Nz0iB1zmMX320_dmoIn9hpqzrCz8f7gq1ub35d36XLh5_31z-WqcmBhzTjRtQmz1sdU-uiKRFEpYuCo4rNc6VbDcagENBoDRUiKtRlBa3QjVALccG-HfaO3r1MSEH2lgx2sQO6iSRwwQtelFkd0e8H1HhH5LGVo7e98rsIyb1PuZFvfcq9T8lFTBHHvxx_mnSPzevwf4ER-HoAWuWkWntLcvUUN-RRNsSzb3B7IDAa2Vr0kozFwWBjPZogG2ff1-UfgoKbig</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Novotny, R.</creator><creator>Cizek, P.</creator><creator>Vitasek, R.</creator><creator>Bartoskova, A.</creator><creator>Prinosilova, P.</creator><creator>Janosovska, M.</creator><general>Elsevier Inc</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120901</creationdate><title>Reversible suppression of sexual activity in tomcats with deslorelin implant</title><author>Novotny, R. ; Cizek, P. ; Vitasek, R. ; Bartoskova, A. ; Prinosilova, P. ; Janosovska, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-20c38c44fb4fb8b5d6e137b550ea3234abfb1cce331dbb17eeeaeb671f3bd3a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>agonists</topic><topic>Animals</topic><topic>cats</topic><topic>Cats - anatomy &amp; histology</topic><topic>Cats - blood</topic><topic>Cats - physiology</topic><topic>Contraception - methods</topic><topic>Contraception - veterinary</topic><topic>Contraceptive Agents, Male - administration &amp; dosage</topic><topic>Down-Regulation - drug effects</topic><topic>Drug Implants</topic><topic>Ejaculation - drug effects</topic><topic>Ejaculation - physiology</topic><topic>germ</topic><topic>GnRH-agonist</topic><topic>Histologic evaluation</topic><topic>human chorionic gonadotropin</topic><topic>Male</topic><topic>Male cat</topic><topic>Organ Size - drug effects</topic><topic>Osmolar Concentration</topic><topic>Recovery of Function - drug effects</topic><topic>Recovery of Function - physiology</topic><topic>semen</topic><topic>Semen collection</topic><topic>seminiferous tubules</topic><topic>Sexual Behavior, Animal - drug effects</topic><topic>Sexual Behavior, Animal - physiology</topic><topic>spermatids</topic><topic>spermatocytes</topic><topic>spermatozoa</topic><topic>surgery</topic><topic>Testis - anatomy &amp; histology</topic><topic>Testis - drug effects</topic><topic>Testis - physiology</topic><topic>Testis size</topic><topic>testosterone</topic><topic>Testosterone - blood</topic><topic>Triptorelin Pamoate - administration &amp; dosage</topic><topic>Triptorelin Pamoate - analogs &amp; derivatives</topic><topic>Withholding Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Novotny, R.</creatorcontrib><creatorcontrib>Cizek, P.</creatorcontrib><creatorcontrib>Vitasek, R.</creatorcontrib><creatorcontrib>Bartoskova, A.</creatorcontrib><creatorcontrib>Prinosilova, P.</creatorcontrib><creatorcontrib>Janosovska, M.</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Theriogenology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Novotny, R.</au><au>Cizek, P.</au><au>Vitasek, R.</au><au>Bartoskova, A.</au><au>Prinosilova, P.</au><au>Janosovska, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reversible suppression of sexual activity in tomcats with deslorelin implant</atitle><jtitle>Theriogenology</jtitle><addtitle>Theriogenology</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>78</volume><issue>4</issue><spage>848</spage><epage>857</epage><pages>848-857</pages><issn>0093-691X</issn><eissn>1879-3231</eissn><abstract>The aim of the study was to assess the efficacy of using a Gn-RH agonist implant (deslorelin, 4.7 mg, Suprelorin) to control sexual activity of male cats and reestablishment of sexual function after the implant removal 4 mo after placement. Using a control group (Group 1, n = 5), 22 domestic tomcats were given the implant subcutaneously in the region of the right shoulder blade and were then divided into two treatment groups. Animals in Group 2 (n = 14) were observed from the date of implant surgery and the observation lasted for 4 mo. In Group 3 (n = 8) all animals were monitored from the date of implant surgery. Then, after 4 mo, all implants were removed and the toms were observed for a further 4 mo. In all animals during their first visit and then in 1-mo intervals, changes in testosterone concentrations were assessed before (T0) and 4 h after (T4) human chorionic gonadotropin (HCG) administration and testis size was measured. In all tomcats, semen collection was performed, using an electroejaculator, in the course of the first visit and then in 2-mo intervals or at the end of observation. Total sperm count was determined in each semen sample. Two to four animals were castrated at weeks 4, 8, 12, 16, 20, 24, 28 and 32 and histologic assessment of the testes was performed. By evaluation of 200 cross sections of seminiferous tubules, the degree of spermatogenic suppression was assessed and animals in Groups 2 and 3 were assigned into groups according to most tubules with the most developed germ cell observed: G1, spermatocytes; G2, round spermatids; G3, elongating spermatids and G4, elongated spermatids. The mean area of Leydig-cell nuclei was calculated. In animals in Group 2, suppression after implant insertion was monitored. T4 concentrations, testis size, and total sperm count gradually decreased (P &lt; 0.01; P &lt; 0.01; and P &lt; 0.05, respectively) within 4 mo after implantation. Histologic evaluation showed a high individual variation in the degree of suppression of spermatogenesis. In animals in Group 3, the implant was removed 4 mo after insertion and the return of sexual activity was monitored. Within 4 mo, T4 concentration and total sperm count increased to the physiological values of intact toms. Testes gradually increased in size and within 4 mo of implant removal almost reached pretreatment size. According to histologic evaluation of the seminiferous tubules, as early as 1 mo after implant removal, all animals were assigned to G4, with most tubules containing elongated spermatids as the most developed germ cells. Treatment with the long-term subcutaneous Gn-RH agonist implant was well tolerated and no adverse treatment-related effects were noted. These results demonstrated efficacy of 4.7 mg deslorelin implant (Suprelorin) with high variability of the effect onset in tomcats. Furthermore, the study revealed a strong need for complex examination, including testis size measurement, monitoring of hormonal changes, spermatological analysis and histologic evaluation, to declare the animal infertile. After the implant removal, all observed parameters confirmed the reversibility of the method and gradual return of sexual activity in toms.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22578617</pmid><doi>10.1016/j.theriogenology.2012.03.035</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0093-691X
ispartof Theriogenology, 2012-09, Vol.78 (4), p.848-857
issn 0093-691X
1879-3231
language eng
recordid cdi_proquest_miscellaneous_1030505628
source ScienceDirect Journals
subjects agonists
Animals
cats
Cats - anatomy & histology
Cats - blood
Cats - physiology
Contraception - methods
Contraception - veterinary
Contraceptive Agents, Male - administration & dosage
Down-Regulation - drug effects
Drug Implants
Ejaculation - drug effects
Ejaculation - physiology
germ
GnRH-agonist
Histologic evaluation
human chorionic gonadotropin
Male
Male cat
Organ Size - drug effects
Osmolar Concentration
Recovery of Function - drug effects
Recovery of Function - physiology
semen
Semen collection
seminiferous tubules
Sexual Behavior, Animal - drug effects
Sexual Behavior, Animal - physiology
spermatids
spermatocytes
spermatozoa
surgery
Testis - anatomy & histology
Testis - drug effects
Testis - physiology
Testis size
testosterone
Testosterone - blood
Triptorelin Pamoate - administration & dosage
Triptorelin Pamoate - analogs & derivatives
Withholding Treatment
title Reversible suppression of sexual activity in tomcats with deslorelin implant
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A51%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reversible%20suppression%20of%20sexual%20activity%20in%20tomcats%20with%20deslorelin%20implant&rft.jtitle=Theriogenology&rft.au=Novotny,%20R.&rft.date=2012-09-01&rft.volume=78&rft.issue=4&rft.spage=848&rft.epage=857&rft.pages=848-857&rft.issn=0093-691X&rft.eissn=1879-3231&rft_id=info:doi/10.1016/j.theriogenology.2012.03.035&rft_dat=%3Cproquest_cross%3E1030505628%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c410t-20c38c44fb4fb8b5d6e137b550ea3234abfb1cce331dbb17eeeaeb671f3bd3a93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1030505628&rft_id=info:pmid/22578617&rfr_iscdi=true